renal cell carcinoma
Conditions
Interventions
WTPA:subcutaneous injection ofWTPA
IFN-a:i.m. or H
non-immunotherapy:Postoperative observation
Sponsors
Lanzhou University second hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Patient is informed and has given written informed consent; 2. Age of men or women >=18 years; 3. Diagnosis of CT/MRI or postoperative pathology is renal cell carcinoma; 4. Doctor evaluate that patients could benefit to use immunotherapy.
Exclusion criteria
Exclusion criteria: 1. Distant metastasis; 2. Any concurrent malignancy or other history cancer; 3. Meanwhile, receive postoperative treatment with systemic immunotherapy, including interferon alpha/gamma, interleukin-2 or any cellular immunotherapies; 4. Patients with congenital or acquired immune deficiency syndromes, or patients taking immunosuppressive drugs; 5. History of multiple drug allergy; 6. Severe uncontrollable active infection; 7. Autoimmune diseases, diabetes or cardiovascular diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;Adverse reactions;Immunological indicator; | — |
Countries
China
Contacts
Public ContactZhiping Wang
Outcome results
None listed